Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Stopped Manually added per CS0177524- Weekly CTEP status report.

Conditions

• Anatomic Stage III Breast Cancer AJCC v8
• Anatomic Stage IV Breast Cancer AJCC v8
• Invasive Breast Carcinoma
• Locally Advanced HER2-Negative Breast Carcinoma
• Locally Advanced Hormone Receptor-Positive Breast Carcinoma
• Locally Advanced Triple-Negative Breast Carcinoma
• Metastatic HER2-Negative Breast Carcinoma
• Metastatic Hormone Receptor-Positive Breast Carcinoma
• Metastatic Triple-Negative Breast Carcinoma
• Unresectable HER2-Negative Breast Carcinoma
• Unresectable Hormone Receptor-Positive Breast Carcinoma
• Unresectable Triple-Negative Breast Carcinoma

Interventions

• PROCEDURE: Biopsy Procedure
• PROCEDURE: Biospecimen Collection
• PROCEDURE: Computed Tomography
• DRUG: Eribulin Mesylate
• PROCEDURE: Magnetic Resonance Imaging
• DRUG: Tolinapant
• PROCEDURE: X-Ray Imaging

Sponsor

National Cancer Institute (NCI)